Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Duchemann

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Cancers|August 14, 2020
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line PembrolizumabRomain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, et al.
ERJ Open Research|April 26, 2018
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancerAdrien Costantini, Jennifer Corny, Vincent Fallet, et al.
Breathe (Sheffield, England)|September 18, 2023
Holistic management of patients with progressive pulmonary fibrosisAna Oliveira, Gaia Fabbri, Thomas Gille, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
CD8<sup>+</sup>PD-1<sup>+</sup> to CD4<sup>+</sup>PD-1<sup>+</sup> ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockersBoris Duchemann, Marie Naigeon, Edouard Auclin, et al.
The European Respiratory Journal|November 6, 2020
Impact of socioeconomic status in patients hospitalised for COVID-19 in the Greater Paris areaLucile Sesé, Yann Nguyen, Etienne Giroux Leprieur, et al.
Annals of Intensive Care|April 18, 2023
ICU admission for solid cancer patients treated with immune checkpoint inhibitorsAnne-Claire Toffart, Anne-Pascale Meert, Florent Wallet, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2019
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitorsLizza E L Hendriks, Gerben Bootsma, Jean Mourlanette, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2019
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French studyCamille Mehlman, Jacques Cadranel, Gaelle Rousseau-Bussac, et al.
The Oncologist|December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancerCamille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
Pathology|June 4, 2024
Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practiceSimon Garinet, Audrey Lupo, Thomas Denize, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Cancers|August 14, 2020
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line PembrolizumabRomain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, et al.
ERJ Open Research|April 26, 2018
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancerAdrien Costantini, Jennifer Corny, Vincent Fallet, et al.
Breathe (Sheffield, England)|September 18, 2023
Holistic management of patients with progressive pulmonary fibrosisAna Oliveira, Gaia Fabbri, Thomas Gille, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
CD8<sup>+</sup>PD-1<sup>+</sup> to CD4<sup>+</sup>PD-1<sup>+</sup> ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockersBoris Duchemann, Marie Naigeon, Edouard Auclin, et al.
The European Respiratory Journal|November 6, 2020
Impact of socioeconomic status in patients hospitalised for COVID-19 in the Greater Paris areaLucile Sesé, Yann Nguyen, Etienne Giroux Leprieur, et al.
Annals of Intensive Care|April 18, 2023
ICU admission for solid cancer patients treated with immune checkpoint inhibitorsAnne-Claire Toffart, Anne-Pascale Meert, Florent Wallet, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2019
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitorsLizza E L Hendriks, Gerben Bootsma, Jean Mourlanette, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2019
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French studyCamille Mehlman, Jacques Cadranel, Gaelle Rousseau-Bussac, et al.
The Oncologist|December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancerCamille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
Pathology|June 4, 2024
Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practiceSimon Garinet, Audrey Lupo, Thomas Denize, et al.
Pageof 9